|
Patent landscape, scope, and claims: |
Executive summary
US Patent 8,114,833 claims GLP-1 agonist injectable formulations and manufacturing/in-device performance methods built around a narrow excipient architecture: propylene glycol as an isotonicity/solubilizing agent at 1–100 mg/mL, combined with disodium phosphate dihydrate buffer and pH 7.0–10.0 (with multiple dependent ranges and embodiments adding a preservative). Claim scope is focused on (i) formulation composition and parameter windows, (ii) specific GLP-1 sequences/derivatives (notably lysine-linked lipophilic substituents and enumerated “Gly/Val/Arg/Lys/His”-variant families), and (iii) method claims directed to replacing a prior isotonicity agent with propylene glycol to reduce deposits, discard rates, and injection-device clogging. The patent estate risk for a would-be generic/biosimilar is driven by whether a product can avoid these excipient windows and performance-oriented method features without reintroducing the same propylene glycol/disodium phosphate/pH package and the enumerated GLP-1 ingredient definitions.
US Patent 8,114,833 scope and claims for GLP-1 agonist injections (propylene glycol + disodium phosphate dihydrate)
US 8,114,833 is an excipient-and-parameter-centric patent: it does not claim a specific branded GLP-1 drug by name, but it defines GLP-1 agonists by sequence families and derivative structural features, then locks those agonists into a buffered propylene glycol formulation with defined pH and concentration ranges. It also claims manufacturing and device-performance improvements premised on switching isotonicity agents to propylene glycol.
What is claimed, in one sentence?
A GLP-1 agonist injection formulation containing propylene glycol (1–100 mg/mL), disodium phosphate dihydrate buffer, and pH 7.0–10.0, plus dependent embodiments that narrow propylene glycol and pH ranges, optionally add a preservative, specify particular GLP-1 agonist sequences/derivatives, and cover methods that reduce deposits/clogging by replacing a prior isotonicity agent with propylene glycol.
Claim map (independent vs dependent and where the IP is “tight”)
| Claim |
Claim type |
Core protected element(s) |
Tightness (practical noninfringement leverage) |
| 1 |
Composition |
GLP-1 agonist + disodium phosphate dihydrate buffer + propylene glycol 1–100 mg/mL + pH 7.0–10.0 |
High for excipient window; avoidable by leaving propylene glycol window, pH window, or buffer type |
| 2–4 |
Composition (dependent) |
Propylene glycol subranges (1–50, 5–25, 8–16 mg/mL) |
High if product targets a different propylene glycol range than any asserted dependent range |
| 5–7 |
Composition (dependent) |
pH subranges (7.0–9.5; 7.0–8.3; 7.3–8.3) |
High leverage if formulation sits outside these narrower pH bands |
| 8–9 |
Composition (dependent) |
Optional preservative (0.1–20 mg/mL) |
Moderate (many injectables include preservatives; harder to design around if you still need a preservative) |
| 10–15 |
Composition (dependent) |
GLP-1 agonist identity: enumerated GLP-1(7-36)/GLP-1(7-37) families, analogues/derivatives; plus lysine residue + lipophilic substituent on ε-amino group; lipophilic substituent C8–40; spacer amino acid; explicit exemplar |
Very high leverage if the active ingredient identity differs materially from the enumerated families/lysine-lipophilic derivative architecture |
| 16–22 |
Method of preparing formulation for injection device |
Two-solution mixing steps (propylene glycol + buffer + preservative dissolved in water; GLP-1 dissolved separately; mix and adjust pH 7.0–10.0) |
Moderate leverage because the final composition window still matters; process steps can be design-around if formulation is made differently and still avoids composition claims |
| 23–24 |
Deposit reduction on equipment during production |
Replace “previous isotonicity agent” with propylene glycol 1–100 mg/mL; formulation has disodium phosphate dihydrate buffer; simulated filling experiment |
High leverage if you do not replace that prior isotonicity agent (or if you avoid the same buffer/propylene glycol architecture) |
| 25 |
Deposit reduction equipment: isotonicity agent list |
Prior isotonicity agent specifically enumerated (sorbitol, sucrose, glycine, mannitol, lactose monohydrate, arginin, myo-inositol, dimethylsulfon) |
High leverage because it narrows the “previous isotonicity agent” universe |
| 26–28 |
Deposit reduction in final product |
Same replacement concept; measure via discarded vials/cartridges |
High leverage if you avoid the same replacement fact pattern and/or measurement endpoint tied to deposits/discard |
| 28 |
Deposit reduction final product: isotonicity agent list |
Broader list (sorbitol, glycerol, sucrose, glycine, mannitol, lactose monohydrate, arginin, myo-inositol, dimethylsulfon) |
High leverage via prior-isotonicity selectivity |
| 29–31 |
Injection-device clogging reduction |
Replace prior isotonicity agent with propylene glycol 1–100 mg/mL; formulation has disodium phosphate dihydrate buffer |
High leverage; list of “prior isotonicity agent” is narrower in 31 |
| 31 |
Clogging reduction: prior isotonicity agent list |
inositol, maltose, glycine, lactose, mannitol |
High leverage: it matters which prior isotonicity agent is “previously utilized” |
H2: What patents protect GLP-1 agonist injectable formulations using propylene glycol and disodium phosphate dihydrate buffer?
US 8,114,833 is itself the core formulation patent here: it protects a specific excipient pair (propylene glycol + disodium phosphate dihydrate buffer) in a defined concentration and pH window, together with GLP-1 agonists defined by sequence/derivative structure.
What in the claim language most narrows coverage?
-
Propylene glycol concentration window (1–100 mg/mL):
- Independent Claim 1 sets 1–100 mg/mL.
- Dependent Claims 2–4 narrow to 1–50, 5–25, and 8–16 mg/mL.
- Method claims also use “between 1–100 mg/mL.”
-
Disodium phosphate dihydrate buffer:
- The claims require that exact buffer component.
-
pH window (7.0–10.0):
- Dependent claims narrow to 7.0–9.5, 7.0–8.3, and 7.3–8.3.
-
GLP-1 identity constraints:
- Claim 10 enumerates GLP-1(7-36)-amide and GLP-1(7-37) plus analogues/derivatives.
- Claim 11 introduces a derivative structural rule: lysine residue plus lipophilic substituent attached to ε-amino group (with optional spacer).
- Claim 12 constrains lipophilic substituent to 8–40 carbon atoms.
- Claim 13 constrains spacer to amino acid.
- Claim 14 gives a concrete example: Arg34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
- Claim 15 lists numerous “Gly8/Val8/Arg/Lys/His” variants and derivatives.
Practical IP exposure logic for formulators
A formulation can avoid Claim 1 if it misses at least one of these three required pillars:
- propylene glycol is outside 1–100 mg/mL, or
- pH is outside 7.0–10.0, or
- buffer is not disodium phosphate dihydrate (or not used as required by the formulation).
Even if composition avoids Claim 1, the method claims can still create risk if the manufacturing/device performance story is matched to the “replace prior isotonicity agent with propylene glycol” fact pattern and uses a disodium phosphate dihydrate-containing formulation.
H2: Which GLP-1 agonist sequences or derivatives are within US 8,114,833 claim scope?
The claims do not cover “all GLP-1 agonists.” They cover GLP-1 agonists defined by specific sequence families and derivatives.
Enumerated GLP-1 agonist families (composition dependent claims)
Claim 10 includes:
- GLP-1(7-36)-amide
- GLP-1(7-37)
- GLP-1(7-36)-amide analogues
- GLP-1(7-37) analogues
- derivatives of any
Claim 15 includes a broader list of specific engineered variants (as written in the claim), including:
- Gly8-GLP-1(7-36)-amide / Gly8-GLP-1(7-37)
- Val8-GLP-1(7-36) amide / Val8-GLP-1(7-37)
- Val8Asp22 variants
- Val8Glu22 variants
- Val8Lys22 variants
- Val8Arg22 variants
- Val8His22 variants
- Arg34GLP-1(7-37)
- Arg26,34Lys36GLP-1(7-36) and Arg26GLP-1(7-37)
- Gly8, Arg26,34Glu37Lys38GLP-1(7-38)
- derivatives of any
Derivative architecture tied to lysine and a lipophilic substituent
Claim 11–14 define a specific derivative template:
- The derivative has a lysine residue.
- A lipophilic substituent is attached to the ε-amino group of that lysine.
- The attachment can include a spacer (optional).
- The lipophilic substituent has 8 to 40 carbon atoms.
- If present, the spacer is an amino acid.
- Claim 14 provides an explicit representative structure/example.
Claim-scope implication for active ingredient selection
If the GLP-1 drug substance is a peptide outside the enumerated sequences and outside the lysine-lipophilic derivative rules, the dependent claims 10–15 narrow coverage sharply. Composition Claim 1 still requires “at least one GLP-1 agonist,” but the practical enforceability of the dependent claims is driven by whether the exact active ingredient falls inside the defined identity buckets.
H2: How do the propylene glycol and pH ranges in US 8,114,833 affect design-around for generic GLP-1 injections?
The patent uses excipient parameter windows as a design lever. In practice, the cleanest route to noninfringement is usually to move one of the required variables outside the claimed ranges.
Parameter windows at a glance
| Parameter |
Claim 1 window |
Narrower dependent windows |
| Propylene glycol concentration |
1–100 mg/mL |
1–50 (C2); 5–25 (C3); 8–16 (C4) |
| pH |
7.0–10.0 |
7.0–9.5 (C5); 7.0–8.3 (C6); 7.3–8.3 (C7) |
How to read this for formulation strategy
- If you choose propylene glycol outside 1–100 mg/mL, you avoid Claim 1.
- If you keep propylene glycol within 1–100 but target pH outside 7.0–10.0, you also avoid Claim 1.
- If you need disodium phosphate dihydrate for stability or buffering, it increases the probability you land inside the formulation “core,” forcing attention onto propylene glycol and pH.
H2: What is the scope of US 8,114,833 method claims for preparing GLP-1 formulations for injection devices?
Claim 16 is a process claim tethered to the composition window. It requires:
- preparing a formulation containing GLP-1 agonist, propylene glycol, disodium phosphate dihydrate buffer, and preservative,
- propylene glycol at 1–100 mg/mL,
- pH 7.0–10.0, and
- a specific mixing workflow:
- (a) first solution: dissolve preservative, propylene glycol, and buffer in water;
- (b) second solution: dissolve GLP-1 agonist in water;
- (c) mixing the first and second solutions;
- adjusting pH to 7.0–10.0.
Dependent limits
Claims 17–19 narrow propylene glycol ranges, while claims 20–22 narrow pH ranges.
Design-around logic
Even if a manufacturer achieves a final formulation inside Claim 1’s excipient windows, Claim 16 can be vulnerable if the formulation is prepared with a different sequence (for example, dissolving GLP-1 into the propylene glycol/buffer/preservative solution in a single step) while still keeping the pH and composition within the required windows.
H2: What deposit-reduction and injection-device clogging methods are claimed in US 8,114,833?
US 8,114,833 covers performance benefits attributed to propylene glycol substitution, framed as replacing a “previously utilized isotonicity agent” with propylene glycol.
Equipment deposits during production
-
Claim 23: replace previously utilized isotonicity agent with propylene glycol (1–100 mg/mL) in a formulation with disodium phosphate dihydrate buffer, to reduce deposits on production equipment.
-
Claim 24: measures reduction via a simulated filling experiment.
-
Claim 25: prior isotonicity agent is one of:
sorbitol, sucrose, glycine, mannitol, lactose monohydrate, arginin, myo-inositol, dimethylsulfon.
Final product deposits (vials/cartridges discarded)
- Claim 26: replace prior isotonicity agent with propylene glycol (1–100 mg/mL), disodium phosphate dihydrate buffer, to reduce deposits in final product.
- Claim 27: measures reduction by fewer vials and/or cartridges discarded due to deposits.
- Claim 28: prior isotonicity agent is one of:
sorbitol, glycerol, sucrose, glycine, mannitol, lactose monohydrate, arginin, myo-inositol, dimethylsulfon.
Injection-device clogging
- Claim 29: replace prior isotonicity agent with propylene glycol (1–100 mg/mL), disodium phosphate dihydrate buffer, to reduce clogging of injection devices.
- Claim 30: measures reduction via simulated in-use study.
- Claim 31: prior isotonicity agent is one of:
inositol, maltose, glycine, lactose, mannitol.
Enforcement mechanics to expect
These method claims are typically most potent in litigation when supported by:
- evidence that the accused process actually replaced a prior isotonicity agent from the enumerated list, and
- performance measurement outcomes that correspond to the claimed measurement endpoints (simulated filling, discard reduction, simulated in-use clogging).
H2: How strong is the patent estate risk from US 8,114,833 for generics or biosimilars of GLP-1 drugs?
Based on claim structure alone:
- The formulation claim (Claim 1) is broad enough to capture many designs that adopt propylene glycol and disodium phosphate buffer with pH 7–10 and a covered GLP-1 agonist.
- The dependent claims tighten into additional subranges and specific active ingredient derivative architectures (lysine-lipophilic substituent derivatives and enumerated variants), which can narrow infringement in practice if the accused active is not on-claim.
What is easiest to design around?
- Propylene glycol: move outside 1–100 mg/mL, or avoid the narrower 5–25 and 8–16 windows when relevant.
- pH: move formulation pH outside the narrower dependent windows; outside 7–10 avoids Claim 1.
- Buffer identity: avoid disodium phosphate dihydrate (if feasible).
What is hardest to design around?
- If the active ingredient itself falls squarely within the enumerated GLP-1 variants/derivatives and the development team already favors propylene glycol + disodium phosphate dihydrate, it becomes difficult to escape Claim 1 without a full reformulation.
H2: What is the Orange Book status of US 8,114,833 and what FDA exclusivity timing matters?
No Orange Book status, listed drug/active ingredient, or expiration dates are provided in the prompt. Without the associated FDA reference product and Orange Book listing data, exclusivity and launch-risk timing cannot be determined from the patent number alone.
H2: What patent litigation or Paragraph IV challenge signals exist for US 8,114,833?
No litigation captions, court filings, or Paragraph IV challenge records are provided in the prompt. Without case identifiers tied to US 8,114,833 and specific ANDA/BLA events, litigation impact cannot be mapped.
Key Takeaways
- US 8,114,833 is centered on a propylene glycol + disodium phosphate dihydrate buffer + pH 7.0–10.0 formulation for GLP-1 agonists defined by enumerated sequences and specific lysine-lipophilic derivative architectures.
- Claim 1 creates the core infringement hook; dependent claims narrow propylene glycol (1–50, 5–25, 8–16 mg/mL) and pH (7.0–9.5, 7.0–8.3, 7.3–8.3), and add optional preservative ranges.
- Dependent claims 10–15 narrow active-ingredient coverage to particular GLP-1(7-36)-amide/GLP-1(7-37) families and specific engineered variants, including a lysine ε-amino lipophilic substituent template (8–40 carbons; optional amino-acid spacer).
- Method claims (Claims 16, 23–31) add enforceable scope around two-solution preparation, and around replacing a “previous” isotonicity agent with propylene glycol to reduce deposits and injection-device clogging, with measurement protocols and enumerated prior isotonicity agents.
FAQs
1) Do US 8,114,833 method claims require the same GLP-1 sequence limitations as the formulation claims?
They require a “GLP-1 agonist formulation” or a GLP-1 agonist within the claimed framework, so the practical scope tracks the same GLP-1 identity constraints used in the formulation provisions.
2) If a product uses propylene glycol but a different buffer than disodium phosphate dihydrate, does it avoid Claim 1?
Claim 1 requires disodium phosphate dihydrate buffer, so using a different buffer can remove an essential claim element.
3) Can an accused product fall outside Claim 1 but still risk dependent claims like Claim 5–7?
If Claim 1 is avoided by missing one required element, dependent claims that rely on Claim 1’s base limitations are also avoided; dependent claims only apply when the Claim 1 base is met.
4) How does the “previously utilized isotonicity agent” language limit method-claim reach?
The method claims tether infringement to a factual substitution from an enumerated prior isotonicity agent list in dependent claims, narrowing the class of switching events.
5) What is the fastest route to a litigation-style noninfringement position based on this claim set?
Address one of the required core pillars first: propylene glycol concentration, formulation pH, or inclusion of disodium phosphate dihydrate buffer, and then analyze whether the active ingredient falls within the enumerated GLP-1 sequences/derivative templates.
More… ↓
⤷ Start Trial
|
